Best Genomics Companies in United Kingdom
The 371 best Genomics companies in United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Nanopore Technologies.
Ranked by disclosed equity funding and recent momentum, the 371 Genomics companies we track across the United Kingdom have pulled in $5.5B in total disclosed funding, with one unicorn among them. That's not speculation. That's filed capital. And the headline number here is Nanopore Technologies, which alone accounts for $1.3B of that pool, followed by Touchlight at $190M and Storm Therapeutics at $98M. The global genomics market sat at roughly $24.3B in 2021 and is forecast to reach $85.1B by 2030, a CAGR of 16.37% that makes this one of the faster-compounding sectors in life sciences right now.
So what's driving it? Declining sequencing costs, rising government support, and a real clinical push toward personalized medicine are the structural tailwinds. Hot themes in coverage include pharmacogenomics, machine learning drug discovery, and hereditary disease genomics, and as shown in 2011 research, the foundational sequencing technology underpinning many of these companies has long been on a steep cost-reduction curve. If you're sizing up this directory, note that investors like Oxford University Innovation, Future Planet Capital, and Scottish Enterprise are the most active backers in this cohort, which tells you something about where institutional conviction is actually sitting.
- Genomics Market Surges with PCR and AI Technologies Projected to Reach
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in United Kingdom
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Nanopore Technologies Manufacturer of portable and benchtop devices for real-time DNA sequencing 87Tech top 11%Market top 21%Funding top 21%Talent top 24% All 9 signals ▾Techtop 11% Markettop 21% Fundingtop 21% Talenttop 24% Newstop 32% Growthtop 39% Moattop 39% Globaltop 42% Fin. healthtop 47% Tech: 82 technologies across 7/8 capability areas · Cloud: Amazon Cloudfront, Amazon S3 Market: 705 employees (top 2% of High Tech) · Revenue ~$234M rank vs industry peers · Fliar Intelligence Index 87/100 | $1.3B | 22 mo ago | 705 705 → 1,352 (+92%) · sector median +74% | Hagan Bayley Co-Founder | StoryblokContentfulSentry+30 | Top 500k | — | 1 launch |
| 2 | MiNA Therapeutics Provider of RNA activation therapeutics | $446M | 59 mo ago | 18 | Pal Saetrom Co-Founder | — | — | 183 patents saRNA gene activation therapeutics targeting HBG1/2, TMEM173, CEBPA for disease treatment | — |
| 3 | Freeline Provider of gene therapy platform for treating chronic diseases | $274M | 70 mo ago | 152 152 → 283 (+86%) · sector median +74% | Michael Parini CEO | — | — | — | — |
| 4 | Gyroscope Developer of gene therapies for eye diseases | $255M | 55 mo ago | 105 | — | — | — | — | — |
| 5 | Touchlight 🦄 Provider of cell-free DNA technology platform for genetic medicine application 60Moat top 22%Patents top 28%Talent top 28%Funding top 29% All 11 signals ▾Moattop 22% Patentstop 28% Talenttop 28% Fundingtop 29% Techtop 30% Innovationtop 39% Markettop 41% Growthbottom 49% Globalbottom 49% Fin. healthbottom 30% Newsbottom 22% Moat: Editorial + unicorn rating 9/10 · IP moat: 106 patents Patents: 106 patents matched (strict assignee match) · 52 filings since 2022 vs 50 in 2017-21 rank vs industry peers · Fliar Intelligence Index 60/100 | $190M | 8 mo ago | 158 158 → 161 (+2%) · sector median +74% | Jonny Ohlson Founder & Co-CEO | WordPressMySQLPHP+33 | Top 10M | 106 patents Patents concentrated in chemistry & materials | 4 launchs |
| 6 | Inivata Developer of liquid biopsy platform for detecting cancer | $189M | 64 mo ago | 81 | Davina Gale Co-founder | — | — | 97 patents Liquid biopsy and nucleic‑acid analysis for cancer detection and monitoring. | — |
| 7 | Biomodal Developer of a duet multiomics platform that generates genetic and epigenetic data | $164M | 55 mo ago | 84 | Peter Fromen CEO | WordPressApple iCloud MailMySQL+31 | Top 5M | 7 patents Genomic and epigenomic analysis tools for DNA sequencing, methylation, and expression prediction | — |
| 8 | Genomics Provider of genomic risk assessment and prevention platform 64Patents top 19%Innovation top 24%Funding top 24%Talent top 28% All 9 signals ▾Patentstop 19% Innovationtop 24% Fundingtop 24% Talenttop 28% Moattop 32% Growthtop 45% Globaltop 46% Techtop 50% Marketbottom 40% Patents: 48 patents matched (strict assignee match) · 33 filings since 2022 vs 13 in 2017-21 Innovation: 48 patents (top 22% of patent-holders) · 33 filings since 2022 vs 13 in 2017-21 rank vs industry peers · Fliar Intelligence Index 64/100 | $161M | 29 mo ago | — | Rebecca H Founder & Principal | HubSpot CMS HubApple iCloud Mailcore-js+14 | Top 5M | 48 patents Software platforms for computational analysis of genomic sequencing data | — |
| 9 | Genomics Provider of a platform for the analysis of genomic sequence data 67Patents top 20%Moat top 21%Innovation top 24%Funding top 30% All 13 signals ▾Patentstop 20% Moattop 21% Innovationtop 24% Fundingtop 30% Partnerstop 32% Producttop 35% Talenttop 35% Markettop 41% Growthtop 49% Fin. healthbottom 46% Globalbottom 45% Techbottom 33% Newsbottom 21% Patents: 48 patents matched (strict assignee match) · 33 filings since 2022 vs 13 in 2017-21 Moat: Editorial + unicorn rating 8/10 · IP moat: 48 patents rank vs industry peers · Fliar Intelligence Index 67/100 | $146M | 29 mo ago | 76 76 → 184 (+142%) · sector median +74% | Peter Donnelly Co-Founder & CEO | — | — | 48 patents Bioinformatics software platforms for computational analysis of genomic sequencing data | 2 awards |
| 10 | ReViral Developer of antiviral compounds for RSV | $121M | 69 mo ago | 28 | Khattereh Ahmadi Co-Founder | — | — | 91 patents Antiviral benzodiazepine derivatives for treating respiratory syncytial virus infections | — |
| 11 | STORM Therapeutics Developer of small molecule inhibitors targeting enzymes that modify RNA 50Funding top 26%Moat top 28%Talent top 28%Patents top 30% All 11 signals ▾Fundingtop 26% Moattop 28% Talenttop 28% Patentstop 30% Innovationtop 36% Newstop 43% Growthtop 45% Marketbottom 46% Globalbottom 42% Fin. healthbottom 39% Techbottom 30% Funding: Raised $98.3M across 8 rounds · 8 rounds over 11 yrs (0.7/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 44 patents rank vs industry peers · Fliar Intelligence Index 50/100 | $98M | 2 mo ago | 28 28 → 14 (-50%) · sector median +74% | Eric Miska Co-Founder & Director | ProcessWirePHPApache HTTP Server+6 | Top 10M | 44 patents Small‑molecule METTL3 inhibitors for epigenetic cancer therapeutics | — |
| 12 | Enara Bio Developer of T-cell based cancer-cell interface for therapeutics | $84M | 20 mo ago | 38 38 → 68 (+79%) · sector median +74% | Kevin Pojasek CEO & President | RubyAnimate.cssVarnish+13 | Top 50M | 63 patents Bispecific polypeptide therapeutics targeting novel cancer antigens for immunotherapy | — |
| 13 | Microbiotica Developer of live bacterial therapeutics and biomarkers for multiple diseases | $83M | 51 mo ago | 42 42 → 55 (+31%) · sector median +74% | Gordon Dougan Co-Founder | WordPressMySQLPHP+13 | Top 10M | 30 patents Engineered therapeutic bacterial formulations for microbiome-based disease treatment | 1 award |
| 14 | Congenica Developer of software for clinical genomic interpretation and variant analysis | $82M | 60 mo ago | 79 | Richard Durbin Co-Founder | — | — | 32 patents Clinical genomic analysis and interpretation tools for prenatal and rare disease diagnostics | 1 partnership |
| 15 | AviadoBio Developer of gene therapies for neurodegenerative disorders | $80M | 54 mo ago | 38 38 → 70 (+84%) · sector median +74% | Do Lee Co-Founder | WordPressApple iCloud MailMicrosoft 365+29 | Top 10M | 3 patents Antisense nucleic‑acid therapies targeting SOD1 for ALS and CNS drug delivery platforms. | 1 launch · 1 partnership |
| 16 | Constructive Bio Provider of a platform for genome and polymer synthesis | $75M | 14 mo ago | 3 | Ola Wlodek CEO | SanityNode.jsTailwind CSS+13 | Top 50M | — | 2 job openings · 1 award |
| 17 | Evonetix Developer of synthetic biology platform | $67M | 40 mo ago | 49 | Raymond Edgson ex-Founder | ZURB FoundationPlyrApache HTTP Server+20 | Top 50M | 92 patents Automated DNA synthesis, enzymatic processing, and DNA-based data storage platforms. | — |
| 18 | QuantuMDx Group Manufacturer of molecular diagnostic platforms and assays for infectious diseases | $57M | 46 mo ago | 98 98 → 53 (-46%) · sector median +74% | Jonathan Halloran CEO & ex-Co-Founder | WordPressMySQLPHP+22 | Top 10M | 154 patents Microfluidic nucleic‑acid diagnostic platforms for rapid qPCR and sample‑prep automation | — |
| 19 | NeoPhore Developer of small molecule therapies to treat cancer | $45M | 28 mo ago | 10 10 → 18 (+80%) · sector median +74% | Alberto Bardelli Co-Founder | ZURB FoundationApache HTTP ServerTypekit+7 | Top 50M | 32 patents Patents concentrated in chemistry & materials | 1 award |
| 20 | C4X Discovery Developer of optimized drug discovery and design services | $43M | 29 mo ago | 46 | — | WordPressMySQLPHP+15 | Top 50M | 130 patents Small‑molecule inhibitors of MALT1, NRF2 agonists, and integrin blockers for immuno‑inflammatory therapy | — |
| 21 | Nucleome Therapeutics Developer of nucleome therapeutics for multiple diseases | $42M | 43 mo ago | 14 | Jim Hughes Co-Founder | WordPressMySQLPHP+26 | Top 10M | — | 1 job opening · 1 award |
| 22 | Ochre Bio Developer of ribonucleic acid therapies for treating chronic liver diseases | $40M | 44 mo ago | 11 | Quin Wills Co-Founder & CEO | WordPressApple iCloud MailGoogle Workspace+26 | Top 10M | — | — |
| 23 | Eagle Genomics Developer of cloud-based software solutions for genomic analysis | $39M | 32 mo ago | 125 | Anthony Finbow CEO | HubSpot CMS HubApple iCloud MailMicrosoft 365+17 | Top 50M | — | — |
| 24 | OXGENE Provider of a platform for mammalian cell engineering | $27M | 11 mo ago | 102 | Len Seymour Co-Founder | — | — | — | — |
| 25 | Sano Provider of clinical trial recruitment and genetic testing research services | $26M | 28 mo ago | 10 | Patrick Short Co-Founder & CEO | HubSpot CMS HubApple iCloud MailGoogle Workspace+16 | Top 5M | — | — |
| 26 | Eleven AI-based RNA drug development platform for researchers 55Growth top 28%Talent top 28%Funding top 31%AI top 45% All 8 signals ▾Growthtop 28% Talenttop 28% Fundingtop 31% AItop 45% Newsbottom 48% Techbottom 44% Globalbottom 37% Marketbottom 25% Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 55/100 | $22M | 14 mo ago | 12 12 → 28 (+133%) · sector median +74% | Shaul Ilan Co-Founder | WordPressMySQLPHP+17 | Top 10M | — | 1 launch |
| 27 | Enhanced Genomics Digital platform focused on decoding the causal biology behind genetic variations to accelerate drug discovery | $19M | 9 mo ago | — | Peter Fraser Co-Founder | Framer SitesVimeoReact+10 | Top 50M | — | — |
| 28 | Broken String Biosciences Developer of biopharmaceutical products & cell therapies by using genome sequencing data | $15M | 33 mo ago | 4 | Felix Dobbs Co-Founder & CEO | WordPress Site EditorWordPressMySQL+24 | Top 50M | 9 patents High-throughput nucleic acid sequencing and DNA double‑strand break detection technologies | 1 job opening |
| 29 | Wobble Genomics Provider of a platform for discovery of nucleic acid biomarkers | $12M | 29 mo ago | 6 | Richard Kuo Founder | WordPressMySQLPHP+17 | Top 50M | 38 patents Normalization and amplification of single‑stranded nucleic acids for biomarker analysis | — |
| 30 | Oxford Biodynamics Developer of personalized diagnostics by identifying biomarkers through epigenetics | $11M | 37 mo ago | 39 39 → 55 (+41%) · sector median +74% | Jon Burrows CEO | Apple iCloud MailMicrosoft 365Bootstrap+17 | Top 10M | 224 patents Chromosome conformation capture diagnostics for cancer detection and biomarker discovery | 1 job opening |
| 31 | Pencil Biosciences Provider of gene-editing technology | $10M | 34 mo ago | 10 10 → 17 (+70%) · sector median +74% | Timothy Utermoehl Co-Founder | — | — | 11 patents Synthetic genome editing platforms for programmable DNA modification | — |
| 32 | Zetta Genomics Provider of genomic data analysis software for clinical labs & research organizations | $10M | 28 mo ago | 4 | — | WordPressMySQLPHP+16 | Top 50M | — | — |
| 33 | Genedrive Provider of point of care molecular diagnostics platform for genotyping and sequence analysis | $9M | 14 mo ago | 43 43 → 45 (+5%) · sector median +74% | Christopher Potten Co-Founder | Apache HTTP ServerFont AwesomejQuery+3 | Top 10M | — | 1 partnership |
| 34 | Dxcover AI-powered device for earlier diagnosis of brain tumors | $9M | 16 mo ago | 16 16 → 31 (+94%) · sector median +74% | Holly Butler Co-Founder & Chief Technical Officer | — | — | 32 patents Early cancer detection via spectroscopic analysis of biological samples | — |
| 35 | Senisca Developer of senotherapeutics that targets the diseases and signs of ageing | $9M | 27 mo ago | 10 10 → 15 (+50%) · sector median +74% | — | — | — | 4 patents Patents concentrated in chemistry & materials | — |
| 36 | Tagomics Developer of genomic-based cancer diagnostic platform | $8M | 12 mo ago | 8 | — | WordPressMySQLPHP+22 | Top 50M | 13 patents Epigenetic and biomolecular profiling technologies for nucleic acid modification analysis | 1 job opening |
| 37 | Plaquetec Developer of a method to profile the biology of coronary artery 22Talent top 28%Moat top 39%Product top 41%News top 43% All 10 signals ▾Talenttop 28% Moattop 39% Producttop 41% Newstop 43% Patentstop 45% Fundingtop 49% Techbottom 49% Innovationbottom 47% Globalbottom 42% Marketbottom 15% Talent: Analyst team rating 4/5 Moat: Editorial + unicorn rating 3/10 · IP moat: 44 patents rank vs industry peers · Fliar Intelligence Index 22/100 | $8M | 1 mo ago | 2 | — | WixSentryBootstrap+11 | Top 50M | 44 patents Vascular catheter systems for intravascular sampling and biomarker‑based prognosis | — |
| 38 | Carcinotech Developer of 3D cancer research models for cancer drug discovery | $8M | 28 mo ago | 1 | Ishani Malhotra CEO | — | — | 10 patents In‑vitro cancer model and microenvironment culture devices for tumor research | — |
| 39 | OptiBiotix Health Developer of microbial strains for the treatment of human metabolic diseases | $4M | 12 mo ago | 12 | — | WordPressMySQLPHP+25 | Top 50M | — | — |
| 40 | BioCaptiva Developer of liquid biopsy technology to detect cancer | $4M | 3 mo ago | 7 | Jeremy Wheeler CEO | — | — | 9 patents Nucleic acid capture and isolation devices for clinical sample processing | — |
| 41 | ReadyGo Provider of diagnostic test and sample collection tools for research labs | $3M | 15 mo ago | 8 | Elaine Warburton Co-Founder | Cart FunctionalitySquarespace CommerceSquarespace+10 | Top 50M | — | — |
| 42 | Biotangents Developer of diagnostic assays for infectious diseases in veterinary medicine | $3M | 18 mo ago | 13 | — | — | — | 6 patents Molecular diagnostics: nucleic acid detection assays and sample‑prep instrumentation. | — |
| 43 | Argonaute RNA Provider of RNA-based therapeutics | $2M | 23 mo ago | 7 | Anthony Parker CEO | — | — | 46 patents Patents concentrated in chemistry & materials | — |
| 44 | Plant Organelle Technologies Developer of technology for reprogramming chloroplast and mitochondrial genomes in crops 40Talent top 45%Global bottom 48%Funding bottom 37% All 3 signals ▾Talenttop 45% Globalbottom 48% Fundingbottom 37% Talent: 2 named leaders on record Global: Investors from 1 country beyond United Kingdom rank vs industry peers · Fliar Intelligence Index 40/100 | $656K | 12 mo ago | — | Anil Day Co-Founder & Director | — | — | — | — |
| 45 | Invenirex Developer of nucleic acid detection instruments | $637K | 6 mo ago | — | Dan Todd Founder & CEO | — | — | — | 1 job opening |
| 46 | Gene Weaver Developer of programmable gene editing technology | $515K | 12 mo ago | — | Niall Armes Founder and CEO | — | — | — | — |
| 47 | Genomes Offers blockchain enabled security for sequenced genomes | $331K | 11 mo ago | 4 | Mark Hahnel Co-Founder | MediumTypeScriptGraphQL+17 | Top 50M | — | 1 launch |
| 48 | Lentitek Developer of technology to enhance lentiviral vector quality and yield | $309K | 15 mo ago | 3 | Leif Anderson Co-Founder | — | — | 3 patents Design and production of genetic expression vectors for recombinant protein synthesis. | — |
| 49 | MeOmics Provider of neural biomarker discovery platform for psychiatric disorders | $185K | 4 mo ago | 6 | Jeremy Hall Co-Founder | — | — | — | — |
| 50 | AMPLY Discovery Provider of AI-based infectious disease drug discovery platform | $20K | 4 mo ago | 2 | Chris Creevey Co-Founder | — | — | — | 1 job opening |
Top 12 Genomics companies in United Kingdom
#1
Series C · Waterbeach, Cambridgeshire · founded 2015 · 28 employees$98.3Mraised▾
Developer of small molecule inhibitors targeting enzymes that modify RNA. These therapeutic agents focus on regulating protein synthesis by modulating the activity of enzymes involved in ribonucleic acid modification. The research and development efforts center on clinical applications for treating various forms of cancer. By targeting specific biological pathways, these inhibitors aim to influence cellular decision-making processes. The development pipeline includes candidates currently undergoing clinical evaluation to assess safety and efficacy in human subjects.
- Apr 2026Series C$56M
- Dec 2022Series B$30M
- May 2022Grant (prize money)—
- Jan 2020Series A$10M
#2
Series B · Hampton, England · founded 2007 · 158 employees$190.1Mraised▾
Provider of cell-free DNA technology platform for genetic medicine application. It leverages a proprietary technology platform and enzymatic manufacturing solutions to develop doggy bone DNA vectors optimized for use in advanced genetic medicines. The platform supports a range of applications which includes mRNA therapeutics, AAV and lentiviral vectors, gene editing, non‑viral therapies, and DNA vaccines.
- Sep 2025Grant (prize money)$714.1K
- Nov 2022Grant (prize money)—
- Jan 2021Series B$178.5M
- Apr 2017Series A$3M
#3
Public · Oxford, England · founded 2005 · 705 employees$1.3Braised▾
Manufacturer of portable and benchtop devices for real-time DNA sequencing. These instruments utilize nanopore sensing technology to analyze native DNA and RNA molecules. The hardware supports various workflows, including library preparation and data analysis through integrated software tools. Applications include genomic research, microbial identification, and transcriptomics. The technology enables the detection of genetic variations and structural changes in biological samples.
- Aug 2024Post IPO$64.2M
- Oct 2023Post IPO$84.5M
- May 2021Series H$270.5M
- Oct 2020Series G$110.1M
#4
Series A · Cambridge, England · founded 2008 · 2 employees$8Mraised▾
Developer of a method to profile the biology of coronary artery. It is building cohorts to endotype the disease for the first time. The approach enables the identification of new disease-specific drug targets. This paves the way for precision medicine for patients with coronary artery disease.
- Apr 2026Series A$5M
- Apr 2024Series A$8M
#5
Seed · Edinburgh, Scotland · founded 2018 · 7 employees$4Mraised▾
Developer of liquid biopsy technology to detect cancer. The company's technology sequences cfDNA isolated from the patient's blood and helps in genome analysis for monitoring and detecting cancer.
- Mar 2026Seed$2.1M
- Jun 2022Seed$2.6M
- Apr 2021Seed$1.4M
#6
Acquired · Oxford, England · founded 2011 · 102 employees$27.1Mraised▾
Provider of a platform for mammalian cell engineering. The company provides plasmid and DNA component products and a plasmid technology called SnapFast. The company is designing DNA sequences, optimizing the expression of proteins, developing cell lines, and improving viral delivery systems. It integrates bioinformatics and gene-editing technology to create a streamlined workflow for cell line production.
- Jul 2025Series A$1M
- May 2020Series A$3.7M
- Mar 2019Series A$8.6M
- Aug 2017Series A$10.3M
#7
Series A · Saffron Walden, England · founded 2022 · 3 employees$75Mraised▾
Provider of a platform for genome and polymer synthesis. The company pioneered the development of methods for reprogramming the genetic code of living organisms that are resistant to a wide variety of viruses, can be programmed to make synthetic, polymers, and even perform entirely new functions. It has applications across a range of industries including novel therapeutics and antibiotics enhanced agriculture, manufacturing, and materials.
- Mar 2025Series A—
- Sep 2024Series A$58M
- Aug 2022Seed$15M
#8
Series A · Cambridge, England · founded 2020$19Mraised▾
Digital platform focused on decoding the causal biology behind genetic variations to accelerate drug discovery. The company uses proprietary GenLink 3D multi-omics platform analyzes genome folding and links disease-associated variants to target genes across the entire human genome, enabling faster identification of high-confidence therapeutic targets for common diseases like autoimmune conditions.
- Sep 2025Series A$19M
#9
Seed · Cambridge, England · founded 2020 · 12 employees$22Mraised▾
AI-based RNA drug development platform for researchers. The company harnesses the power of combinatorial chemistry and AI to transform RNAi drug development into a programmable process against influenza and SARS-CoV-2.
- Apr 2025Grant (prize money)$3M
- Feb 2025Grant (prize money)$320K
- Aug 2022Seed$18M
- Aug 2022Grant (prize money)$4M
#10
Series B · Oxford, England · founded 2016 · 38 employees$84.1Mraised▾
Enara Bio is developing a T-cell based cancer-cell interface for therapeutics. The company is involved in the immune interface for cancer biology to develop and characterize immunotherapy targets, like dark antigens derived from the genomic dark matter or antigens presented by the cancer-specific MR1 receptor. The company offers proprietary TCR-directed T-cell therapies to target tumor homogeneity and cancer vaccines to generate polyclonal autologous ex vivo stimulation of T-cell products.
- Oct 2024Series B$32.5M
- May 2021Series A$16.3M
- Nov 2019Series A$17.5M
- Apr 2018Seed$7.8M
#11
Series A · Birmingham, England · founded 2020 · 8 employees$8.4Mraised▾
Developer of genomic-based cancer diagnostic platform. It offers a platform technology based on a non-invasive blood test that captures the unmodified locations of the genome and analyzes the changes that occur during cancer.
- Jun 2025Grant (prize money)$1.2M
- Feb 2024Series A$8.4M
#12
Public · Manchester, England · founded 2000 · 43 employees$9.3Mraised▾
Provider of point of care molecular diagnostics platform for genotyping and sequence analysis. The company offers MT-RNR1 ID Kit, a pharmacogenetic test to prevent antibiotic induced deafness in infants, and Genedrive HCV ID Kit is used to screen for hepatitis C and COVID-19.
- Apr 2025Post IPO$1.6M
- Nov 2018Post IPO$7.7M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in the United Kingdom
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 3,509 United Kingdom-affiliated papers.
- European Bioinformatics Institute204
- University of Cambridge194
- University of Oxford193
- University College London180
- Imperial College London179
- Genome27→142
- Gene20→131
- Transcriptome5→84
- Disease2→62
- Immune system1→44
- Disease4→116
- Gene6→81
- Cancer6→46
- Genome10→43
- Phenotype1→27
- Disease7→79
- Cancer4→28
- Immune system2→25
- Context (archaeology)3→22
- Genome5→21
Where bioinformatics is researched across United Kingdom
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing bioinformatics patents in the United Kingdom
United Kingdom bioinformatics patent filing is cooling — 19 filings from 7 assignees (2016–2025), led by Deepmind TECH, BISN Laboratory Services, Gardner Steve; annual filings 5→2.
- Deepmind TECH13
- BISN Laboratory Services3
- Gardner Steve1
- Lemon1
- BISN LAB Services1
- Samsung1
- Beijing Youzhuju Network TECH1
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.